Clinical trials: Post-COVID-19
Pulmonary Alveolar Proteinosis, COPD
Use of cSVF Via IV Deployment for Residual Lung Damage After Symptomatic COVID-19 Infection
COVID-19 Viral Global Pandemic resulting in post-infection pulmonary damage, including Fibrotic Lung Disease due to inflammatory and reactive protein secretions damaging pulmonary alveolar structure and functionality.
- Conditions
- Pulmonary Alveolar Proteinosis, COPD, Idiopathic Pulmonary Fibrosis, Viral Pneumonia
- Trial name
- GARM-COVID19 (NCT04326036)
- Testing
- Microcannula Harvest Adipose Derived tissue stromal vascular fraction (tSVF), Centricyte 1000, IV Deployment Of cSVF In Sterile Normal Saline IV Solution
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Black Tie Medical, Inc.
Post Acute COVID-19 Syndrome
Digital Health Intervention Based on Artificial Intelligence to Support the Personalized Recovery of Long COVID Patients Affected by Fatigue (AIDA)
The AIDA feasibility study builds upon mental health and technology acceptance theoretical frameworks. It examines the feasibility of a mobile-based digital program to support patients with long covid affected by fatigue.
- Trial name
- AIDA (NCT05483829)
- Testing
- Adhera® Fatigue for Long COVID program
- Where
- Spain
- Volunteers
- 15 people
- Sponsor
- Adhera Health, Inc.
SARS-CoV-2 Infection
VLA2001 Booster in Adult Participants After Priming With mRNA COVID-19 Vaccine and/or Natural SARS-CoV-2 Infection
This is a clinical study to investigate the safety, tolerability and immunogenicity of a VLA2001 booster vaccination in participants aged 18 years and older. In total approximately 275 participants are planned to be enrolled.
- Trial name
- NCT05364242
- Testing
- VLA2001
- Where
- 4 sites in Netherlands, New Zealand
- Volunteers
- 178 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
COVID-19 Pneumonia
Evaluation of Immunogenicity, Safety and Antibody Persistence of COVID-19 Booster Vaccine (Produced in Wuhan) in Patients With Hypertension and/or Diabetes
To evaluate the post-marketing immunogenicity, safety and antibody persistence of the third dose (booster) of Covid-19 vaccine in patients aged 60 years or older with hypertension and/or diabetes.
- Trial name
- NCT05104437
- Testing
- Covid-19 vaccine (0-1-4 schedule), Covid-19 vaccine (0-1-6 schedule)
- Where
- 3 sites in China
- Volunteers
- 1,440 people, healthy volunteers welcome
- Sponsor
- China National Biotec Group Company Limited
Long Covid
To Investigate Efficacy, Pharmacodynamics, and Safety of BC 007 in Participants With Long COVID
This study is an interventional, randomized, multinational, multicenter, double-blind, phase 2 study with a follow-up period of 90 days.
- Trial name
- BLOC (NCT05911009)
- Where
- 16 sites in Austria, Finland and 3 more
- Volunteers
- 119 people
- Sponsor
- Berlin Cures GmbH
SARS-CoV-2
Post-Marketing Safety Study in Japan of Shock and Anaphylaxis After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in Persons in at High Risk of Severe COVID-19
The goal of this study is to confirm the onset status of hypersensitivity reactions including shock and anaphylaxis observed after vaccination with this drug in persons with underlying diseases who are considered to have a high…
- Trial name
- NCT05894499
- Where
- Japan
- Volunteers
- 13,309 people
- Sponsor
- ModernaTX, Inc.
Traumatic Brain Injury (TBI), Acquired Brain Injury
LearningRx Cognitive Training for Brain Injury
The purpose of this investigation is to conduct a series of case studies on the impact of LearningRx cognitive training on cognitive skills, daily functioning, and workplace self-efficacy for participants with Traumatic Brain…
- Conditions
- Traumatic Brain Injury (TBI), Acquired Brain Injury, Post COVID-19 Cognitive Impairment
- Trial name
- NCT02918994
- Testing
- LearningRx cognitive training
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Gibson Institute of Cognitive Research
COVID-19 Pneumonia, COVID-19 Respiratory Infection
Phase 2/Phase 3 Study To Evaluate The Efficacy And Safety Of Ramatroban Along With The Standard Of Care In Subjects Hospitalized For COVID Pneumonia
Phase II/Phase III study to evaluate the safety and efficacy of Ramatroban 75 mg tablet against Placebo in subjects hospitalized for pneumonia due to SARS-CoV-2 infection.
- Trial name
- NCT05706454
- Testing
- Ramatroban
- Where
- 7 sites in India
- Volunteers
- 324 people
- Sponsor
- KARE Biosciences
2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection
Leidos-Enabled Adaptive Protocol (LEAP-CT) for Evaluation of Post-exposure Prophylaxis for Newly-infected COVID-19 Patients
This study is designed to test the efficacy and safety of combinations of two well-understood agents - famotidine and celecoxib.
- Conditions
- 2019 Novel Coronavirus Disease, 2019 Novel Coronavirus Infection, 2019-nCoV Disease, 2019-nCoV Infection
- Trial name
- NCT05077969
- Testing
- Famotidine, Celecoxib
- Where
- 15 sites in United States
- Volunteers
- 4 people
- Sponsor
- Leidos Life Sciences
Post COVID-19 Condition
Post-COVID-19 Patients With Trak Tool
The clinical trial aims to analyse the effectiveness of a physiotherapeutic exercise program delivered through the telerehabilitation tool (Trak) compared to a booklet-based rehabilitation format in post-COVID-19 patients.
- Trial name
- TRAK-COVID (NCT06492551)
- Testing
- Trak exercise prescription protocol, Conventional rehabilitation plan in the gym
- Where
- Spain
- Volunteers
- 80 people
- Sponsor
- Trak Health Solutions S.L.
SARS-CoV-2 Infection
Evusheld Japan PMS_Japan Post-Marketing Surveillance (PMS)
To investigate intends to evaluate the incidence of adverse drug reactions (ADRs) in individuals who receive Evusheld in clinical practice to determine its post-marketing safety profile in Japanese.
- Trial name
- NCT05687877
- Where
- 18 sites in Japan
- Volunteers
- 366 people
- Sponsor
- AstraZeneca
COVID-19, SARS-CoV-2
Study Will Assess the Safety, Neutralizing Activity and Efficacy of AZD3152 in Adults With Conditions Increasing Risk of Inadequate Protective Immune Response After Vaccination and Thus Are at High Risk of Developing Severe COVID-19
AZD3152, a single mAb, is being developed to have broad neutralizing activity across known SARS-CoV-2 variants of concern for pre-exposure prophylaxis of COVID-19.
- Trial name
- NOVELLA (NCT06057064)
- Testing
- Biological: AZD3152
- Where
- 6 sites in Russia
- Volunteers
- 116 people
- Sponsor
- AstraZeneca
COVID-19, Diabetes Mellitus
Incidence of Diabetes After a COVID-19 Infection
Prospective observational study of the POINTED consortium to evaluate whether new diagnoses of diabetes mellitus, occur significantly more frequently in the post-acute phase of a laboratory-confirmed SARS-CoV-2 infection than in…
- Trial name
- POINTED_Diab (NCT05524792)
- Testing
- no interventional study
- Where
- Germany
- Volunteers
- 157,134 people
- Sponsor
- InGef - Institute for Applied Health Research Berlin GmbH
COVID-19
Immunogenicity and Safety of a Third Dose of COVID-19 Vaccine(Vero Cell), Inactivated in the Elderly
This is an open phase Ⅲ clinical trial of COVID-19 vaccine (Vero cell), inactivated manufactured by Sinovac Research \& Development Co., Ltd.The purpose of this study is to evaluate Immunogenicity and safety of a third dose at…
- Trial name
- NCT05398926
- Testing
- COVID-19 Vaccine (Vero cell), Inactivated
- Where
- China
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Sinovac Life Sciences Co., Ltd.
Post-Acute COVID-19 Syndrome, Lung Disease With Polymyositis
Efficacy and Safety of Longidaza® for the Treatment of Patients With Residual Changes in the Lungs After COVID-19
The goal of this clinical study is to evaluate the efficacy and safety of Longidaza®, lyophilisate for preparation of solution for injection, at a dose of 3000 IU compared to placebo in the treatment of adult patients with…
- Conditions
- Post-Acute COVID-19 Syndrome, Lung Disease With Polymyositis, Fibrosis, Lung Diseases, Interstitial
- Trial name
- NCT06383819
- Testing
- Longidaza®
- Where
- 30 sites in Russia
- Volunteers
- 392 people
- Sponsor
- NPO Petrovax
COVID-19
Assessment of Mental Health in Healthcare Workers Exposed to COVID-19 Patients
The recent COVID-19 outbreak has put the health care workers on the frontline to interact and provide support to the patients. Based on previous disease outbreak-associated studies, it is evident that these individuals are at a…
- Trial name
- BADS-PTSD (NCT04473118)
- Testing
- Survey
- Where
- Qatar
- Volunteers
- 25,000 people
- Sponsor
- Hamad Medical Corporation
COVID-19
A Study to Understand How the Use of Paxlovid Affected Healthcare Use in People With Pre-existing Conditions.
This is a cohort study that will include Paxlovid (nirmatrelvir-ritonavir) treatment eligible for people with a positive SARS-CoV-2 diagnostic test and at least one COVID-19 symptom.
- Trial name
- NCT07090486
- Testing
- nirmatrelvir-ritonavir
- Where
- United States
- Volunteers
- 14,000 people
- Sponsor
- Pfizer
Depression, Post-COVID-19 Syndrome
Evaluation of DEPREXIL in Patients With Clinical Depression Through Psychological and Neuroendocrine Assessment
Clinical depression is a mood disorder that affects people of all ages with symptoms such as sadness, anger or frustration, appetite changes, difficulty concentrating and suicidal thoughts.
- Conditions
- Depression, Post-COVID-19 Syndrome, Depression Mild, Depression Moderate
- Trial name
- NCT06496087
- Testing
- DEPREXIL
- Where
- Colombia
- Volunteers
- 100 people
- Sponsor
- Catalysis SL
COVID-19, Vaccine Adverse Reaction
National Vaccine Adverse Event Reporting Survey and Etiology
If your serious vaccine-induced adverse event has been entered in the CDC Vaccine Adverse Event Reporting System (VAERS) we are interested in enrolling you for this study in order to log your symptoms.
- Conditions
- COVID-19, Vaccine Adverse Reaction, Vaccine Reaction, Vaccine or Biological Substance, Unspecified Causing Adverse Effects in Therapeutic Use
- Trial name
- NVAERS (NCT05095844)
- Testing
- vaccinated
- Where
- United States
- Volunteers
- 100,000 people
- Sponsor
- Neuroganics LLC
Covid19
Efficacy of Adaptogens in Patients With Long COVID-19
The aim of this clinical trial of a fixed combination of standardized extracts from Rhodiola rosea roots, Schisandra chinensis berry and Eleutherococcus senticosus root (ADAPT-232) in COVID-19 patients is to demonstrate possible…
- Trial name
- NCT04795557
- Testing
- ADAPT-232 oral solution
- Where
- Georgia
- Volunteers
- 100 people
- Sponsor
- Swedish Herbal Institute AB